S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:LYEL

Lyell Immunopharma - LYEL Price Target & Analyst Ratings

$3.28
+0.01 (+0.31%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.15
$3.34
50-Day Range
$2.78
$4.22
52-Week Range
$2.74
$8.74
Volume
806,623 shs
Average Volume
1.00 million shs
Market Capitalization
$817.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Lyell Immunopharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$7.33
123.58% Upside
High Prediction$11.00
Average Prediction$7.33
Low Prediction$4.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Hold
Hold
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.33$8.33$14.67$24.25
Predicted Upside123.58% Upside61.29% Upside156.41% Upside79.56% Upside
Get Lyell Immunopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.


LYEL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LYEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Lyell Immunopharma Stock vs. The Competition

TypeLyell ImmunopharmaMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.65
2.46
Consensus RatingHoldBuyHold
Predicted Upside123.58% Upside1,302.23% Upside8.14% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/24/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$7.00 ➝ $4.00+34.23%
11/11/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$13.00 ➝ $7.00+41.13%
11/9/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$12.00 ➝ $11.00+100.73%
7/12/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$22.00+38.54%
7/12/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+57.43%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












LYEL Price Target - Frequently Asked Questions

What is Lyell Immunopharma's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Lyell Immunopharma stock is Hold based on the current 2 hold ratings and 1 buy rating for LYEL. The average twelve-month price prediction for Lyell Immunopharma is $7.33 with a high price target of $11.00 and a low price target of $4.00. Learn more on LYEL's analyst rating history.

Do Wall Street analysts like Lyell Immunopharma more than its competitors?

Analysts like Lyell Immunopharma less than other Medical companies. The consensus rating for Lyell Immunopharma is Hold while the average consensus rating for medical companies is Buy. Learn more on how LYEL compares to other companies.

Is Lyell Immunopharma being downgraded by Wall Street analysts?

Over the previous 90 days, Lyell Immunopharma's stock had 2 downgrades by analysts.

Does Lyell Immunopharma's stock price have much upside?

According to analysts, Lyell Immunopharma's stock has a predicted upside of 57.71% based on their 12-month price targets.

What analysts cover Lyell Immunopharma?

Lyell Immunopharma has been rated by HC Wainwright, Morgan Stanley, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:LYEL) was last updated on 2/2/2023 by MarketBeat.com Staff